Boao Yiling Launches 12 Global Approved Medical Devices and Therapeutics to Advance from 'International Healthcare' to 'National Healthcare'

Original Title: Boao Yiling Launches 12 Specially Approved Global Drugs and Medical Devices, Promoting the Transition from “International Healthcare” to “National Healthcare” Source: Jiupai News

On September 14, the Boao Yiling 2021 Press Conference on the "Four Special Permissions, Three Synchronizations," New Technologies, New Drugs & Medical Devices, and New Services in the Free Trade Port Pilot Zone was held in Boao. Twelve medical devices and technologies, already approved overseas but not yet available in China, were centrally launched to enhance the accessibility of high-quality medical resources at the grassroots level.

The specially licensed pharmaceuticals and medical devices introduced by Yiling Group this time are the Continuous Glucose Monitoring System from Germany's Bayer AG and the Plexr Plus from Italy's GMV,Bloomage BiotechThe 12 internationally advanced medical devices and pharmaceuticals, including HAIRCARE, from Co., Ltd. focus on multiple sectors such as medical aesthetics and sports rehabilitation. Unlike previously introduced products that primarily targeted clinical applications, these 12 products incorporate broader wellness and rehabilitation concepts, offer a more convenient and user-friendly experience, and will further enhance the medical service capabilities of the Lecheng Pilot Zone.

Zhao Xuan, Head of the Health Brand Management and Operations Department at Yiling Group, told reporters that these 12 pharmaceutical and medical device products will fill existing gaps in Yiling Hospital’s treatment portfolio. Specifically, treatment protocols covering hair transplantation as well as volume and shape modification of the male genitalia will be integrated into the Group’s current membership-based treatment system.

Making “international healthcare” accessible to the “general public”, the Hainan Free Trade Port and its suite of preferential policies have attracted numerous top-tier international pharmaceutical and medical device companies and healthcare institutions to cluster and develop, while also drawing leading medical expert teams from both home and abroad to establish their presence. At this press conference, numerous executives from multinational pharmaceutical and medical device companies gathered on-site to share in the development dividends of the Hainan FTP, collaborating to advance real-world data research in Lecheng and expedite the market launch of specially approved drugs and medical devices in China.

Han Yaoxing, General Manager of North Asia at Dornier MedTech (Asia) Co., Ltd., stated that the company hopes to leverage the unique healthcare advantages of the Hainan Free Trade Port, particularly its special concession policies, to introduce one of the world's most advanced shockwave therapy devices to Yiling. Through this strategic collaboration and pilot implementation with Yiling, they also aim to collect more real-world data, thereby laying the groundwork and preparing for the company's upcoming regulatory approval applications for Class III indications.

It is reported that, as of the end of August 2021, the Lecheng Pilot Zone had approved the introduction of 175 varieties of specially permitted drugs and medical devices. Meanwhile, new anti-tumor drugs and rare disease medications have achieved a major breakthrough from zero to 100, preliminarily realizing the "three synchronizations" of medical technology, equipment, and pharmaceuticals with internationally advanced standards.

【Source: Qionghai Civilization Network】

Disclaimer: The copyright of this article belongs to the original author. If there are any source errors or if it infringes upon your legitimate rights and interests, please contact us via email, and we will promptly address the matter. Email address: jpbl@wccm.sinanet.com

Report/Feedback

On September 14, the Boao Yiling 2021 Launch Conference for the Free Trade Port Pilot Zone’s “Four Special Approvals, Three Synchronizations,” New Technologies, New Drugs & Devices, and New Services was held in Boao. Twelve medical devices and technologies, already marketed overseas but not yet available in China, were collectively unveiled to promote the decentralization of high-quality medical resources.

The specially licensed drugs and medical devices introduced by Yiling Group this time comprise 12 internationally advanced medical devices and pharmaceuticals, including Bayer AG's Continuous Glucose Monitoring System, Italy's GMV Plexr Plus, and Bloomage Biotech Co., Ltd.'s HAIRCARE. These products focus on multiple fields such as medical aesthetics and sports rehabilitation. Unlike previously introduced products that primarily targeted clinical applications, these 12 items incorporate a broader wellness and rehabilitation philosophy and offer a more convenient and user-friendly experience, thereby further enhancing the medical service capabilities of the Lecheng Pilot Zone.

Zhao Xuan, Director of the Health Brand Management and Operations Department at Yiling Group, told reporters that these 12 pharmaceutical and medical device products will fill a gap in the therapeutic offerings at Yiling Hospital. Specifically, comprehensive systems for hair restoration and transplantation, as well as treatments for volume and shape modification of the male reproductive organs, will be integrated into the Group’s existing membership-based treatment programs.

Transitioning "international healthcare" to "national healthcare," the Hainan Free Trade Port and its suite of policy advantages have attracted numerous high-caliber international pharmaceutical and medical device enterprises and healthcare institutions to cluster and develop, as well as leading expert teams from both domestic and international medical fields to settle in. At this press conference, numerous executives from multinational pharmaceutical and medical device companies gathered on-site to share in the dividends of the Hainan Free Trade Port's development and collaborate to advance real-world data research in Lecheng, aiming to accelerate the launch of specially licensed drugs and medical devices in China.

Han Yaoxing, General Manager of the North Asia Region at Dornier MedTech (Asia) Co., Ltd., stated that the company hopes to leverage the Hainan Free Trade Port’s unique advantages in healthcare, particularly its special franchise policies, to introduce one of the world’s most advanced shockwave therapy devices to Yiling. By forging a strategic partnership with Yiling to conduct pilot trials, they also aim to collect more real-world data, thereby laying the groundwork and preparing for the future regulatory submission of Class III indications.

It is reported that as of the end of August 2021, the Boao Lecheng Pilot Zone had approved the introduction of 175 types of specially licensed drugs and medical devices. Meanwhile, new anti-tumor drugs and rare disease medications have achieved a major breakthrough from 0 to 100, initially realizing the "three synchronizations" of medical technology, equipment, and pharmaceuticals with internationally advanced standards.

【Source: Qionghai Civilization Network】

Disclaimer: The copyright of this article belongs to the original author. If there are any attribution errors or if your legitimate rights and interests are infringed, please contact us via email and we will promptly address the matter. Email address: jpbl@wccm.sinanet.com

Report / Feedback